Oncternal Therapeutics Gross Profit vs. Operating Margin
| ONCT Stock | USD 1.14 0.02 1.72% |
Gross Profit | First Reported 2004-03-31 | Previous Quarter -5.5 M | Current Value -5.1 M | Quarterly Volatility 7.6 M |
For Oncternal Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Oncternal Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Oncternal Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Oncternal Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Oncternal Therapeutics over time as well as its relative position and ranking within its peers.
Oncternal |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncternal Therapeutics. If investors know Oncternal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncternal Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.69) | Revenue Per Share 0.73 | Quarterly Revenue Growth 1.76 | Return On Assets (0.76) | Return On Equity (1.50) |
The market value of Oncternal Therapeutics is measured differently than its book value, which is the value of Oncternal that is recorded on the company's balance sheet. Investors also form their own opinion of Oncternal Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Oncternal Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncternal Therapeutics' market value can be influenced by many factors that don't directly affect Oncternal Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncternal Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncternal Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncternal Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Oncternal Therapeutics Operating Margin vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Oncternal Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncternal Therapeutics value to that of its competitors to determine the firm's financial worth. Oncternal Therapeutics is regarded fourth in gross profit category among its peers. It also is regarded fourth in operating margin category among its peers . At this time, Oncternal Therapeutics' Gross Profit is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Oncternal Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Oncternal Operating Margin vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Oncternal Therapeutics |
| = | (31.49 M) |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Oncternal Therapeutics |
| = | (17.57) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Oncternal Operating Margin Comparison
Oncternal Therapeutics is currently under evaluation in operating margin category among its peers.
Oncternal Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Oncternal Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Oncternal Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Oncternal Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Oncternal Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 3 K | 3.1 K | |
| Operating Income | -41.7 M | -43.8 M | |
| Net Loss | -39.5 M | -41.5 M | |
| Income Tax Expense | -41.7 M | -39.6 M | |
| Income Before Tax | -39.5 M | -41.5 M | |
| Total Other Income Expense Net | 2.2 M | 2.3 M | |
| Net Loss | -41.7 M | -43.8 M | |
| Non Operating Income Net Other | 903.9 K | 503.1 K | |
| Net Loss | -50.8 M | -53.3 M | |
| Net Interest Income | 2.3 M | 2.4 M | |
| Interest Income | 2.3 M | 2.4 M | |
| Change To Netincome | 8.5 M | 9 M | |
| Net Loss | (13.43) | (14.10) | |
| Income Quality | 0.81 | 0.56 | |
| Net Income Per E B T | 1.13 | 1.24 |
Oncternal Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Oncternal Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Oncternal Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Oncternal Therapeutics' important profitability drivers and their relationship over time.
Use Oncternal Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncternal Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncternal Therapeutics will appreciate offsetting losses from the drop in the long position's value.Oncternal Therapeutics Pair Trading
Oncternal Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Oncternal Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncternal Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncternal Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncternal Therapeutics to buy it.
The correlation of Oncternal Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncternal Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncternal Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncternal Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Oncternal Therapeutics position
In addition to having Oncternal Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Printing and Publishing Thematic Idea Now
Printing and Publishing
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Oncternal Stock Analysis
When running Oncternal Therapeutics' price analysis, check to measure Oncternal Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncternal Therapeutics is operating at the current time. Most of Oncternal Therapeutics' value examination focuses on studying past and present price action to predict the probability of Oncternal Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncternal Therapeutics' price. Additionally, you may evaluate how the addition of Oncternal Therapeutics to your portfolios can decrease your overall portfolio volatility.